GENSCRIPT BIO: Legend will present the latest data at the American Society of Hematology Annual Meeting
GENSCRIPT BIO announced that its joint venture Legend Biotech will present the latest data related to CARVYKTI® and other pipelines at the 67th Annual Meeting of the American Society of Hematology to be held in San Diego from December 6 to 9, 2025. The company submitted Form 6-K to the U.S. Securities and Exchange Commission on November 3, 2025
According to the Zhitong Finance APP, GENSCRIPT BIO (01548) announced that Legend Biotech Corporation (a joint venture of the company, whose shares are listed in the form of American Depositary Shares on the NASDAQ Global Select Market in the United States) submitted a Form 6-K to the U.S. Securities and Exchange Commission on November 3, 2025 (New York time) (before the Hong Kong trading session on November 4, 2025) and announced that it will present the latest data related to CARVYKTI® and other pipelines at the 67th American Society of Hematology Annual Meeting to be held in San Diego from December 6 to 9, 2025
